Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH4IRP)

Drug Name

2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine Drug Info

Synonyms

1H-Benzimidazol-5-amine, 2-(4-thiazolyl)-; CHEMBL370420; 25893-06-5; 5-Aminothiabendazole; 5-amino-2-(thiazol-4-yl)-1H-benzimidazole; 2-(4-Thiazolyl)-1H-benzimidazol-5-amine; AC1Q4XVD; 2-(thiazol-4-yl)-1H-benzo[d]imidazol-5-amine; AC1L35H8; SCHEMBL4367564; CTK7D8516; CUDHOGCHOXYXRZ-UHFFFAOYSA-N; MolPort-004-293-518; ZINC13679482; BDBM50180749; AKOS000129404; MCULE-2929987645; 5-amino-2-thiazol-4-yl-1H-benzoimidazole; 2-Thiazol-4-yl-3H-benzoimidazol-5-ylamine; 2-(1,3-thiazol-4-yl)-3H-benzimidazol-5-amine

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 134912
CAS Number: CAS 25893-06-5
TTD Drug ID: DMH4IRP

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Methionine aminopeptidase 2 (METAP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Beloranib	DM71CK8	Solid tumour/cancer	2A00-2F9Z	Phase 3	[2]
D-Methionine	DMMKGBP	N. A.	N. A.	Phase 3	[3]
ZGN-1061	DM9KB7A	Type 2 diabetes	5A11	Phase 2	[4]
M8891	DMZ9NVP	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
SDX-7320	DMU0Q6L	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
PPI-2458	DMSAQBC	Autoimmune diabetes	5A10	Phase 1	[6]
TNP-470	DMT0QK8	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[7]
2-Methyl-2-Propanol	DMHM5GJ	Discovery agent	N.A.	Investigative	[3]
2-(phenylsulfonamido)-5-propylbenzoic acid	DMDGAHO	Discovery agent	N.A.	Investigative	[8]
5-p-Tolyl-1H-[1,2,3]triazole	DM2W0AD	Discovery agent	N.A.	Investigative	[9]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Methionine aminopeptidase 2 (METAP2)	TTZL0OI	MAP2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Subtype-selectivity of metal-dependent methionine aminopeptidase inhibitors, Bioorg. Med. Chem. Lett. 20(14):4038-4044 (2010).
2	2011 Pipeline of Zafgen.
3	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
4	The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trial. Diabetes Obes Metab. 2020 Jul;22(7):1215-1219.
5	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
6	Metabolites of PPI-2458, a selective, irreversible inhibitor of methionine aminopeptidase-2: structure determination and in vivo activity. Drug Metab Dispos. 2013 Apr;41(4):814-26.
7	Tumor suppression by a rationally designed reversible inhibitor of methionine aminopeptidase-2. Cancer Res. 2003 Nov 15;63(22):7861-9.
8	Development of sulfonamide compounds as potent methionine aminopeptidase type II inhibitors with antiproliferative properties. Bioorg Med Chem Lett. 2006 Jul 1;16(13):3574-7.
9	4-Aryl-1,2,3-triazole: a novel template for a reversible methionine aminopeptidase 2 inhibitor, optimized to inhibit angiogenesis in vivo. J Med Chem. 2005 Sep 8;48(18):5644-7.